Compare
Chemomab Therapeutics Ltd. vs Actuate Therapeutics, Inc. vs CalciMedica, Inc. vs Exicure, Inc.
| Latest fiscal year | Chemomab Therapeutics Ltd. CMMB | Actuate Therapeutics, Inc. ACTU | CalciMedica, Inc. CALC | Exicure, Inc. XCUR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$8.99M | -$22.23M | -$29.56M | -$4.95M |
| EPS (Diluted) | $0.018 | -$1.06 | -$1.97 | -$0.79 |
| Operating cash flow | -$11.13M | -$19.21M | -$21.18M | -$8.55M |
| Free cash flow | -$11.13M | n/a | -$21.21M | -$8.56M |
| Cash & equivalents | $7.56M | $13.16M | $11.52M | n/a |
| Total assets | $13.81M | $14.04M | $13.59M | $14.04M |
| Total liabilities | $1.48M | $6.11M | $20.23M | $10.12M |
| Shareholders' equity | $12.33M | $7.92M | -$6.64M | $3.93M |
| Return on year-end equity | -72.9% | -280.5% | n/a | -126.0% |
| Shares outstanding | n/a | 23.25M | 15.44M | 6.37M |
Revenue, most recent five fiscal years
| Fiscal year | Chemomab Therapeutics Ltd. | Actuate Therapeutics, Inc. | CalciMedica, Inc. | Exicure, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $500.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $28.83M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | -$483.0K Ended 2021-12-31 |